L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's Disease

被引:40
作者
Guridi, Jorge [1 ]
Obeso, Jose A. [1 ,2 ]
Rodriguez-Oroz, Maria C. [1 ,2 ]
Lozano, Andres A. [3 ]
Manrique, Miguel [1 ]
机构
[1] Univ Navarra, Dept Neurosci, Div Neurosurg, Univ Clin, Pamplona 31008, Spain
[2] Univ Navarra, Ctr Neurosci, Pamplona 31008, Spain
[3] Univ Toronto, Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada
关键词
deep brain stimulation; L-dopa-induced dyskinesia; pallidotomy; Parkinson's disease; subthalamic nucleus; subthalamotomy; thalamotomy;
D O I
10.1227/01.neu.0000315998.58022.55
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: To assess the impact of different surgical targets and techniques, such as ablation and deep brain stimulation, to treat patients with L-dopa-induced dyskinesia (LID), a major therapeutic complication of Parkinson's disease. METHODS: This review analyzes the effects of early surgical procedures to treat hyperkinesia and the current methods and targets used to combat LID in Parkinson's disease, which are mainly thalamotomy, pallidotomy, and deep brain stimulation of the globus pallidus internus and the subthalamic nucleus. RESULTS: Available information indicates that surgery of the globus pallidus internus and thalamus (the pallidal receiving area) and of the subthalamic nucleus has a pronounced antidyskinetic effect. This effect is associated with a concomitant improvement in the parkinsonian ("off"-medication) state. Although it is more profound with pallidal and subthalamic surgery, such an effect can also be observed to some extent with thalamic surgery. The latter is attributable to the fact that surgery of the ventralis intermedius is primarily effective for treating tremor. An integral pallidothalamic pathway is needed for dyskinesia to be expressed. Thus, LID is less frequent after subthalamotomy or deep brain stimulation of the subthalamic nucleus through a functional effect mediated by the physiological normalization of the motor system and by an indirect effect associated with a reduction in the daily dose Of L-dopa. CONCLUSION: Surgery is the only treatment available for Parkinson's disease that can predictably improve both the parkinsonian motor syndrome and LID. The exact mechanisms involved in these effects are not well understood. Pallidal and thalamic surgery affecting pallidal relays reduce LID frequency by disrupting the pallidothalamic circuit, probably eliminating the neuronal activity associated with dyskinesia. Alternatively, the antidyskinetic effect of subthalamic nucleus surgery may in part be attributable to a reduction in the L-dopa dose as well as to the stabilization of the basal ganglia circuits after the surgical procedure.
引用
收藏
页码:311 / 323
页数:13
相关论文
共 50 条
[21]   L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson's Disease Is Associated With the Fluctuational Release of Norepinephrine in the Sensorimotor Striatum [J].
Wang, Yong ;
Wang, Hui Sheng ;
Wang, Tao ;
Huang, Chen ;
Liu, Jian .
JOURNAL OF NEUROSCIENCE RESEARCH, 2014, 92 (12) :1733-1745
[22]   Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease [J].
Chen, Yuan-Hao ;
Kuo, Tung-Tai ;
Wang, Vicki ;
Cheng, Pin-Wen ;
Huang, Eagle Yi-Kung ;
Ma, Kuo-Hsing ;
Greig, Nigel H. ;
Olson, Lars ;
Hoffer, Barry J. ;
Tseng, Kuan-Yin .
JOURNAL OF PARKINSONS DISEASE, 2024, 14 (05) :941-964
[23]   Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease [J].
Kobylecki, Christopher ;
Cenci, M. Angela ;
Crossman, Alan R. ;
Ravenscroft, Paula .
JOURNAL OF NEUROCHEMISTRY, 2010, 114 (02) :499-511
[24]   Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update [J].
AlShimemeri, Sohaila ;
Fox, Susan H. ;
Visanji, Naomi P. .
EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (02) :131-144
[25]   Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats [J].
Nascimento, G. C. ;
Bariotto-dos-Santos, K. ;
Leite-Panissi, C. R. A. ;
Del-Bel, E. A. ;
Bortolanza, M. .
NEUROTOXICITY RESEARCH, 2018, 34 (04) :799-807
[26]   β-Lapachone ameliorates L-DOPA-induced dyskinesia in a 6-OHDA-induced mouse model of Parkinson's disease [J].
Ryu, Young-Kyoung ;
Park, Hye-Yeon ;
Go, Jun ;
Lee, In-Bok ;
Choi, Young-Keun ;
Lee, Chul-Ho ;
Kim, Kyoung-Shim .
MOLECULAR MEDICINE REPORTS, 2021, 23 (03)
[27]   Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology [J].
Wang, Yong ;
Zhang, Ge-Juan ;
Sun, Yi-Na ;
Yao, Lu ;
Wang, Hui-Sheng ;
Du, Cheng-Xue ;
Zhang, Li ;
Liu, Jian .
BEHAVIOURAL BRAIN RESEARCH, 2018, 347 :175-183
[28]   Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and L-DOPA-induced dyskinesia [J].
Bourdenx, Mathieu ;
Nilsson, Anna ;
Wadensten, Henrik ;
Falth, Maria ;
Li, Qin ;
Crossman, Alan R. ;
Andren, Per E. ;
Bezard, Erwan .
NEUROBIOLOGY OF DISEASE, 2014, 62 :307-312
[29]   Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease [J].
Fiorentini, Chiara ;
Savoia, Paola ;
Savoldi, Daria ;
Bono, Federica ;
Busi, Chiara ;
Barbon, Alessandro ;
Missale, Cristina .
MOVEMENT DISORDERS, 2016, 31 (04) :512-520
[30]   A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease [J].
Ko, Wai Kin D. ;
Li, Qin ;
Cheng, Long Yun ;
Morelli, Micaela ;
Carta, Manolo ;
Bezard, Erwan .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 813 :10-16